Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05866861 · ClinicalTrials.gov registry record · Phase 1
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
A Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), sponsored by Cugene.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 11
- Study locations
NCT05866861 is a Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus) that is active but no longer recruiting, run by Cugene. The registered enrollment target is 40 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (89% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT05866861, a Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), is active but no longer recruiting, sponsored by Cugene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 11
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CUG252
Study Locations (11)
Florida
- Site 1002 - Clearwater
- Site 1009 - Tampa
Ohio
- Site 1010 - Columbus
- Site 1005 - Middleburg Heights
Texas
- Site 1006 - Dallas
- Site 1004 - Mesquite
Alabama
- Site 1001 - Anniston
California
- Site 1011 - La Jolla
Georgia
- Site 1007 - Lawrenceville
Pennsylvania
- Site 1003 - Duncansville
Washington
- Site 1012 - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05866861
The ClinicalTrials.gov registry entry for NCT05866861 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (89% lower). The listed sponsor is Cugene, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05866861 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05866861 about?
NCT05866861 is a clinical study titled "A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus". The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT05866861?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-04-24. Estimated completion is 2025-04-01.
What conditions does trial NCT05866861 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, SLE (Systemic Lupus), Autoimmune.
What interventions are being tested in trial NCT05866861?
The interventions under investigation include: Placebo (DRUG), CUG252 (DRUG).
Who is sponsoring clinical trial NCT05866861?
This trial is sponsored by Cugene, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05866861 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.